Earlier detection, precision medicine, and non-invasive testing are reshaping how cancer is found, classified, and monitored. Grand View Research sizes the global cancer diagnostics market as follows:

• 2025 market size: USD 119.8 billion
• 2026 estimate: USD 126.4 billion
• 2033 forecast: USD 191.1 billion
• Growth rate: CAGR of 7.1% from 2026 to 2033

The sections below cover the macro forces behind that growth, the technologies driving it, and the companies competing for share.

Key Macro Trends Driving the Market

1. A rising global cancer burden

Cancer is the world's second leading cause of death after cardiovascular disease. The Global Burden of Disease analysis in The Lancet (September 2025) reported about 18.5 million new cases and 10.4 million cancer deaths in 2023. It projects cases will reach 30.5 million by 2050. Tobacco and alcohol use, obesity, sedentary lifestyles, poor diet, and pollution all contribute to incidence. An ageing population adds to demand for screening and diagnostic assessment.

2. The shift toward early detection

Health systems are putting more weight on catching cancer early, when outcomes are better and treatment costs are lower. Government and private investment in screening programs and diagnostic infrastructure is expanding. Japan's national screening programs, for example, reach over 94% of the population.

3. Precision oncology and personalized medicine

Treatment planning now relies on biomarker testing, molecular profiling, and genomic analysis. Companion diagnostics are paired with targeted therapies, which widens diagnostic testing across the whole cancer care pathway. Companies are also combining genomic and clinical data in molecular decision-support systems.

4. Insurance and reimbursement dynamics

Public insurance dominated the market and is expected to grow fastest as governments bring liquid biopsy, AI-driven imaging, and NGS into routine care. Private insurers such as UnitedHealthcare, Anthem, Aetna, and Cigna already cover a wide range of tests, and private cover is gaining ground in Germany, Australia, and Japan.

5. The cost barrier

High costs remain the main restraint. NGS, PET, liquid biopsy, and advanced imaging need heavy capital investment, specialized staff, and ongoing spending on reagents and maintenance. In emerging economies with limited insurance coverage, these costs slow adoption of newer technologies.

6. Regional momentum

North America led with roughly 40% of revenue in 2025, and the U.S. was the largest country market. Asia Pacific is the fastest-growing region, supported by healthcare reforms, urbanization, and rapidly ageing populations. Latin America and the Middle East & Africa are earlier-stage but promising. Many MEA markets are still largely untapped because organized screening programs are limited.

Want the full data behind this analysis? The report includes market estimates and forecasts for 2021–2033, segment-level trends, and company profiles. Download Free Sample Report

Technological Breakdown

By product: consumables lead

Consumables (antibodies, kits and reagents, probes) held 59.6% of 2025 revenue and are projected to grow fastest. Recurring use in screening, biomarker testing, and pathology sustains this segment. Instruments cover pathology systems, PCR, NGS, microarrays, and imaging. Services cover interpretation, genomic profiling, and analytics, and benefit from software-enabled platforms.

By type: IVD, LDT, and imaging

• In vitro diagnostics (IVD) led with 52.5% share. Automated systems that improve throughput and reduce errors are a key driver. The IVD technologies covered include PCR, ISH, IHC, NGS, microarrays, flow cytometry, and immunoassays.
• Laboratory-developed tests (LDTs) are expected to grow at the highest CAGR. Labs can bring them to market quickly, and they support personalized therapy decisions. Guardant Health's Shield blood test for colorectal cancer began as an LDT.
• Imaging spans MRI, CT, PET, mammography, and ultrasound. Novel imaging solutions and AI integration are improving accuracy, as with Hologic's FDA-cleared Genius Digital Diagnostics System for cervical cancer screening.

By test type: biopsy and liquid biopsy

Biopsy is estimated to grow fastest because it supports early detection, shows how aggressive a cancer is, and guides treatment selection. Liquid biopsy is a major opportunity. In May 2026, Guardant Health received FDA approval for Guardant360 Liquid CDx for comprehensive tumor profiling. In July 2024, the FDA approved Shield for colorectal cancer screening in average-risk adults aged 45 and older.

By application

Breast cancer led with 15.9% share, driven by R&D in advanced screening tools. Colorectal cancer is expected to grow fastest, spurred by demand for accurate early-detection tools.

By end use

Laboratories led with 52.1%, as hospitals increasingly rely on diagnostic labs. Home-based tests are growing quickest, at 7.16% CAGR, as payers and providers look to reduce unscheduled hospitalizations and emergency visits.

Competitive Landscape

The market has two groups of players with different strategies.

Established players include Roche, Abbott, GE HealthCare, QIAGEN, BD, Siemens Healthineers, Philips, Hologic, Thermo Fisher Scientific, and Illumina. They compete through broad portfolios across imaging, molecular diagnostics, pathology, and companion diagnostics. Their strengths are brand recognition, regulatory expertise, and global distribution. Their weaknesses are high R&D costs, complex approvals, and the constant need to keep innovating.

Emerging players include Guardant Health, Tempus AI, Caris Life Sciences, Exact Sciences, Freenome, Grail, Natera, and Haystack Oncology. They focus on liquid biopsy, MRD testing, AI-enabled diagnostics, and genomic profiling. They move fast and are strong in niche applications. Their limits are smaller global reach, dependence on external funding, and the challenge of commercializing at scale.

Recent strategic moves show where the competition is heading:

• Dec 2024: Guardant Health partnered with Boehringer Ingelheim to advance Guardant360 CDx as a companion diagnostic for zongertinib in HER2-mutant NSCLC.
• Nov 2024: Danaher announced two new Centers of Innovation in Diagnostics to advance precision medicine, including a hub in Newcastle, UK, hosted by Leica Biosystems.
• Apr 2023: Quest Diagnostics acquired Haystack Oncology to expand MRD testing.
• Feb 2023: Roche expanded its companion diagnostics collaboration with Janssen.
• Jun 2023: Blue Earth Diagnostics received FDA approval for POSLUMA, a PSMA-targeted PET imaging agent for prostate cancer.

The pattern is consistent: partnerships with pharma, acquisitions in MRD and liquid biopsy, and regional expansion. The winners are likely to combine testing technologies, data, and therapeutic partnerships into integrated oncology offerings.

The Road Ahead

Demand is structural, since cancer incidence is rising and healthcare systems are prioritizing early detection. Technology is moving toward non-invasive, genomic, and AI-enabled diagnostics. The main challenge is making these tools affordable and reimbursable outside high-income markets. Companies that solve the access problem will capture much of the growth through 2033.

Need insights tailored to your business? Add regions, segments, or competitor detail, or request a fully bespoke study. Purchase includes free customization. Customize This Report